Alnylam Pharmaceuticals: Challenges In The TTR Space And Few Late-Stage Catalysts Are A Concern

2025-12-13 22:45:00 ET

The last three months have been a little more challenging for Alnylam Pharmaceuticals (ALNY), with slowing sales at a key rival raising concerns about the overall health of the critical transthyretin amyloidosis (or TTR) space, particularly with more competition likely on the way in a year or so. On top of that, while Alnylam has numerous high-potential clinical assets in human studies, there won’t be much late-stage data to drive sentiment in 2026....

Read the full article on Seeking Alpha

For further details see: